Breaking News, Collaborations & Alliances

Innovent and Incyte Form Collaboration for Three Clinical-stage Product Candidates in China

Incyte to receive $60 million upfront and up to $331.5 million if development and regulatory milestones are reached

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Innovent Biologics and Incyte have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor).   Innovent will pay Incyte $40 million in cash up front, and Incyte shall be eligible to receive an additional $20 million in consideration in connection with the first investigational new drug (IND) application by Innovent in China, whi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters